189 related articles for article (PubMed ID: 11557491)
1. In vitro activity of the ketolide ABT-773.
Barry AL; Fuchs PC; Brown SD
Antimicrob Agents Chemother; 2001 Oct; 45(10):2922-4. PubMed ID: 11557491
[TBL] [Abstract][Full Text] [Related]
2. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.
Credito KL; Lin G; Pankuch GA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Jan; 45(1):67-72. PubMed ID: 11120946
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Brueggemann AB; Doern GV; Huynh HK; Wingert EM; Rhomberg PR
Antimicrob Agents Chemother; 2000 Feb; 44(2):447-9. PubMed ID: 10639382
[TBL] [Abstract][Full Text] [Related]
4. Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.
Rospide MF; Biedenbach DJ; Jones RN
Int J Antimicrob Agents; 2001 Jun; 17(6):451-5. PubMed ID: 11397614
[TBL] [Abstract][Full Text] [Related]
5. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Neuhauser MM; Prause JL; Danziger LH; Pendland SL
Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the new ketolide ABT-773 against community acquired respiratory tract isolates and Viridans Streptococci.
Casellas JM; Tomé G; Visser M; Gliosca L
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):107-12. PubMed ID: 11858905
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
Brown SD; Rybak MJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci.
Singh KV; Malathum K; Murray BE
Antimicrob Agents Chemother; 2001 Dec; 45(12):3640-3. PubMed ID: 11709359
[TBL] [Abstract][Full Text] [Related]
11. Antipneumococcal activity of ABT-773 compared to those of 10 other agents.
Davies TA; Ednie LM; Hoellman DM; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Jul; 44(7):1894-9. PubMed ID: 10858350
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children.
Johnson CN; Benjamin WH; Gray BM; Crain MC; Edwards KM; Waites KB
Int J Antimicrob Agents; 2001 Dec; 18(6):531-5. PubMed ID: 11738340
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.
Dubois J; St -Pierre C
Diagn Microbiol Infect Dis; 2001; 40(1-2):35-40. PubMed ID: 11448561
[TBL] [Abstract][Full Text] [Related]
14. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.
Mason EO; Lamberth LB; Wald ER; Bradley JS; Barson WJ; Kaplan SL
Antimicrob Agents Chemother; 2003 Jan; 47(1):166-9. PubMed ID: 12499186
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.
Abbanat D; Webb G; Foleno B; Li Y; Macielag M; Montenegro D; Wira E; Bush K
Antimicrob Agents Chemother; 2005 Jan; 49(1):309-15. PubMed ID: 15616310
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.
Agouridas C; Denis A; Auger JM; Benedetti Y; Bonnefoy A; Bretin F; Chantot JF; Dussarat A; Fromentin C; D'Ambrières SG; Lachaud S; Laurin P; Le Martret O; Loyau V; Tessot N
J Med Chem; 1998 Oct; 41(21):4080-100. PubMed ID: 9767644
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of a novel ketolide ABT-773 against invasive strains of Streptococcus pneumoniae.
Weiss K; de Azavedo J; Restieri C; Quach C; Laverdiere M; Rubin E; Gourdeau M; Low DE
J Antimicrob Chemother; 2001 Sep; 48(3):407-9. PubMed ID: 11533007
[TBL] [Abstract][Full Text] [Related]
19. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
20. A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: synthesis and structure-activity relationships.
Nomura T; Iwaki T; Narukawa Y; Uotani K; Hori T; Miwa H
Bioorg Med Chem; 2006 Jun; 14(11):3697-711. PubMed ID: 16460944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
